Comparison of warfarin dosage fluctuation with time in therapeutic range for bleeding or thromboembolism rate in Chinese patients

被引:7
作者
Yu, Hsi-Yu [1 ,2 ]
Tsai, Hsiao-En [3 ]
Chen, Yih-Sharng [1 ,2 ]
Hung, Kuan-Yu [2 ,4 ,5 ]
机构
[1] Natl Taiwan Univ Hosp, Dept Surg, Taipei, Taiwan
[2] Natl Taiwan Univ, Coll Med, Taipei, Taiwan
[3] Natl Taiwan Univ Hosp, Dept Surg, Hsin Chu Branch, Hsin Chu City, Taiwan
[4] Natl Taiwan Univ Hosp, Dept Internal Med, Taipei, Taiwan
[5] Natl Taiwan Univ Hosp, Dept Internal Med, Hsin Chu Branch, Hsin Chu City, Taiwan
关键词
Warfarin; Warfarin dosage fluctuation; International normalized ratio; Bleeding; Thromboembolism; NONVALVULAR ATRIAL-FIBRILLATION; ORAL ANTICOAGULANT; JAPANESE PATIENTS; RISK-FACTORS; MANAGEMENT; INTENSITY; QUALITY; ADHERENCE; COUNTRIES; CENTERS;
D O I
10.1016/j.jfma.2018.07.021
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background/Purpose: Warfarin treatment benefits vary with the clinical skill of warfarin dosage adjustment. However, optimal dosage adjustment in response to the out-of-range international normalized ratio (INR) is not completely understood. Methods: Data for 2014-2016 from an integrated health care information system of a single hospital were analyzed. Based on their warfarin dosage fluctuation (WDF), defined as the standard deviation of all prescribed warfarin dosages divided by the mean dosage, the patients were classified into Groups 1 (0-0.10), 2 (0.10-0.20), and 3 (>0.20). Target and in-range INRs were 2.0-2.5 and 1.5-3.0, respectively. Based on time in therapeutic range (TTR), patients were also categorized into Groups 1 (<0.6), 2 (0.6-0.9), and 3 (>0.9). The primary outcome was emergency department visits for bleeding or thromboembolism (TE) events. Results: Eighty-three events were retrieved from 17,397 records (1834 patients). Annual incidence rates were 0.9%, 2.5%, and 4.5% for WDF Groups 1, 2, and 3, respectively (p < 0.05), and 2.3%, 1.7%, and 1.7% for TTR Groups 1, 2, and 3, respectively (p = 0.41). Area under the receiver operator characteristic curves for WDF and TTR were 0.686 and 0.519, respectively, indicating that WDF exhibited superior predictive performance than TTR. Conclusion: High WDF rather than low TTR was associated with increased bleeding and TE incidence rates. Copyright (C) 2018, Formosan Medical Association. Published by Elsevier Taiwan LLC.
引用
收藏
页码:611 / 618
页数:8
相关论文
共 50 条
  • [31] Proton pump inhibitors co-prescribed with warfarin reduce warfarin control as measured by time in therapeutic range
    Bertram, Victoria
    Yeo, Kelly
    Anoopkumar-Dukie, Shailendra
    Bernaitis, Nijole
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2019, 73 (11)
  • [32] Time in therapeutic range Warfarin anticoagulation for atrial fibrillation in a community-based practice
    Gateman, Derek
    Trojnar, Melissa Elizabeth
    Agarwal, Gina
    CANADIAN FAMILY PHYSICIAN, 2017, 63 (10) : E425 - E431
  • [33] Apixaban Compared With Warfarin for Stroke Prevention in Atrial Fibrillation Implications of Time in Therapeutic Range
    Gallego, Pilar
    Antonio Vilchez, Juan
    Lane, Deirdre A.
    CIRCULATION, 2013, 127 (22) : 2163 - 2165
  • [34] The effect of nurse-led care on stability time in therapeutic range of INR in ischemic stroke patients receiving warfarin
    Amiri, Mina
    Kargar, Marzieh
    Borhanihaghighi, Afshin
    Soltani, Fahimeh
    Zare, Najafe
    APPLIED NURSING RESEARCH, 2017, 33 : 96 - 101
  • [35] Female Sex, Time in Therapeutic Range, and Clinical Outcomes in Atrial Fibrillation Patients Taking Warfarin
    Senoo, Keitaro
    Lip, Gregory Y. H.
    STROKE, 2016, 47 (06) : 1665 - U623
  • [36] Impact of provision of time in therapeutic range value on anticoagulation management in atrial fibrillation patients on warfarin
    Huang, Duo
    Wong, Chi-Lap
    Cheng, Kwan-Wa
    Chan, Pak-Hei
    Yue, Wen-Sheng
    Wong, Chun-Ka
    Ho, Chi-Wai
    Wong, Ian C. K.
    Chan, Esther W.
    Siu, Chung Wah
    POSTGRADUATE MEDICAL JOURNAL, 2018, 94 (1110) : 207 - 211
  • [37] Alternative Calculations of Individual Patient Time in Therapeutic Range While Taking Warfarin: Results From the ROCKET AF Trial
    Singer, Daniel E.
    Hellkamp, Anne S.
    Yuan, Zhong
    Lokhnygina, Yuliya
    Patel, Manesh R.
    Piccini, Jonathan P.
    Hankey, Graeme J.
    Breithardt, Guenter
    Halperin, Jonathan L.
    Becker, Richard C.
    Hacke, Werner
    Nessel, Christopher C.
    Mahaffey, Kenneth W.
    Fox, Keith A. A.
    Califf, Robert M.
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2015, 4 (03): : e001349
  • [38] Age is associated with time in therapeutic range for warfarin therapy in patients with atrial fibrillation
    Marcatto, Leiliane Rodrigues
    Sacilotto, Luciana
    da Costa Darrieux, Francisco Carlos
    Hachul, Denise Tessariol
    Scanavacca, Mauricio Ibrahim
    Krieger, Jose Eduardo
    Pereira, Alexandre Costa
    Junior Lima Santos, Paulo Caleb
    ONCOTARGET, 2016, 7 (34) : 54194 - 54199
  • [39] Health Economic Analysis of Rivaroxaban and Warfarin for Venous Thromboembolism Management in Chinese Patients
    Fung, Ka-Po
    Chan, Kei-Hong
    Ng, Vivien
    Tsui, Ping-Tim
    You, Joyce H. S.
    CARDIOVASCULAR DRUGS AND THERAPY, 2019, 33 (03) : 331 - 337
  • [40] Required warfarin dose and time in therapeutic range in patients with diagnosed Nonalcoholic Fatty Liver Disease (NAFLD) or Nonalcoholic Steatohepatitis (NASH)
    Wen, Xuerong
    Wang, Shuang
    Taveira, Tracey H.
    Akhlaghi, Fatemeh
    PLOS ONE, 2021, 16 (09):